GHRP-2, also called pralmorelin, is a synthetic hexapeptide growth hormone secretagogue that binds the ghrelin receptor and prompts the pituitary to release a pulse of growth hormone. Everything the research and clinical literature reports about its dosing, timing, and administration describes an investigational compound rather than an approved therapy, so the material below documents reported practice, not a protocol to follow. The compound ships as a freeze-dried powder that has to be reconstituted before it can be measured or injected.
In the published literature GHRP-2 is described as a reconstituted subcutaneous injection dosed most often near 100 micrograms or roughly 1 microgram per kilogram of body weight, timed to an empty stomach, and it carries no approved therapeutic indication in most jurisdictions.
The compound arrives freeze-dried because peptides hold their potency far better as a dry solid than in solution, so the published handling accounts all begin from a powder that has to be brought into solution. How that reconstitution is carried out sets both the concentration and, as the literature stresses, the sterility of every later withdrawal.
Published handling accounts describe reconstituting GHRP-2 with a sterile diluent such as bacteriostatic water, where two milliliters added to a five milligram vial produces a 2500 microgram per milliliter solution.
The dose figures in the record cluster tightly, and the reason is physiological rather than conventional: the pituitary response saturates, so past a threshold more peptide buys diminishing growth hormone alongside a rising chance of cortisol and prolactin surges. That saturation point is why reported research amounts have not simply climbed on the assumption that more is better.
The most frequently cited single research amount of GHRP-2 sits near 100 micrograms, or roughly 1 microgram per kilogram of body weight, above which the pituitary response saturates rather than climbing in proportion to the dose.
Timing is a real variable in the reported accounts rather than an afterthought, because the growth hormone pulse the peptide triggers can be sharply dampened by the metabolic and hormonal state of the body when a dose lands. The literature points to food, sleep, and the body's own inhibitory signaling as the three states that decide how large that pulse turns out.
Elevated glucose and insulin from a carbohydrate- or fat-heavy meal suppress growth hormone release, which is why the literature repeatedly describes GHRP-2 being dosed on an empty stomach and sometimes near sleep onset.
The route decides how fast and how high the growth hormone pulse rises, and the record separates the four that have been tried by how well the peptide survives the path into the bloodstream. Subcutaneous injection dominates the accounts because it balances reliable absorption against a smooth response without the sharp spike of a direct vascular route.
| Route | Absorption | Reported use |
|---|---|---|
| Subcutaneous | Reliable, smooth pulse | The route named most often |
| Intravenous | Immediate, high, brief | Controlled research measuring pituitary reactivity |
| Oral | Degraded by digestion | Generally ineffective for this peptide |
| Intranasal | Lower, more variable | Explored as a needle-free alternative |
Subcutaneous injection into the fatty layer beneath the skin is the route reported most often for GHRP-2, while intravenous delivery is reserved for controlled research and oral dosing is described as ineffective because digestive enzymes degrade the peptide before absorption.
Frequency in the reported patterns follows directly from how briefly a single dose works. The peptide has a short half-life and the pulse it evokes rises and falls within a window of roughly one to two hours, so the record describes a genuine contrast between one large event a day and several smaller ones spread across it.
GHRP-2 has a short half-life with a growth hormone pulse that rises and falls within roughly one to two hours, which is why reported patterns range from a single daily pulse to two or three spaced doses that mimic natural episodic secretion.
The boundaries around this peptide begin with its legal status and widen from there, because it is not an approved therapeutic in most jurisdictions and acts directly on the endocrine system rather than on growth hormone in isolation. That combination is the reason the record frames its use as belonging under qualified medical supervision, with monitoring that reaches past growth hormone itself.
GHRP-2 is not an approved therapeutic drug in most jurisdictions and is prohibited in and out of competition by anti-doping authorities, which is why the literature treats professional evaluation and endocrine monitoring as non-negotiable context rather than optional.
Storage splits cleanly into two phases, and the dividing line is reconstitution. A sealed dry powder is relatively hardy, but once a diluent is added the solution becomes perishable, and heat and light are what drive its decline.
| Property | Sealed lyophilized powder | Reconstituted solution |
|---|---|---|
| Stability | Relatively hardy | Perishable once mixed |
| Storage | Cool, dark place | Refrigerated, shielded from light |
| Usable window | Extended periods | A matter of weeks, potency declining |
| Freezing | Extends dry shelf life | Store-once; repeated freeze-thaw degrades |
A sealed lyophilized GHRP-2 vial stays stable for extended periods in a cool, dark place, but once reconstituted it is kept refrigerated and is generally described as usable for a matter of weeks, with cloudiness, particulates, or discoloration cited as signs of degradation.
No single universal figure fits, because several personal variables move what the literature treats as an appropriate amount. The record points to body weight, age, the research endpoint, and coexisting conditions as the factors that pull the target in different directions, which is exactly why matching an amount to a person is documented as a clinical judgment.
Body weight, age, baseline endocrine output, the research endpoint, and coexisting conditions such as glucose intolerance all shift what the literature treats as an appropriate GHRP-2 amount, making it a clinical judgment rather than a fixed rule.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
